Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 19, 2026Clinical Cancer Research

Abstract PS5-04-27: Quality of life in patients with advanced breast cancer (aBC) treated with ribociclib (RIB) in the real-world RIBANNA trial

View Full Paper
Ask AI
Bookmark
Share

Authors

PFP. A. FaschingCBC. BruckerTDT Decker

Discussion

Loading...

Member takes

Overview

Non-interventional study examines quality of life in advanced breast cancer with ribociclib treatment, suggesting positive implications for patient outcomes.

Key Points

  • To evaluate the quality of life in patients with advanced breast cancer receiving ribociclib in a real-world setting.
  • Conducted the RIBANNA prospective, multicenter non-interventional study in Germany.
  • Collected patient-reported outcomes using the EORTC QLQ-C30 questionnaire.
  • Analyzed time to deterioration in global health status and subscales over a median follow-up of 83.6 months.
  • Focused QoL analysis on the ribociclib cohort due to the small size of other treatment groups.
  • Quality of life measured by the EORTC QLQ-C30 showed stable mean changes over time with no significant deterioration.
  • Global health status did not change significantly, though an initial trend toward improvement was observed.
  • Median time to deterioration for global health status was 12.2 months; for role functioning, it was 12.0 months.
  • About 50% of patients experienced a deterioration in quality of life by at least 10% after 12 months.

Cite This Study

Fasching et al. (2026) studied this question.

synapsesocial.com/papers/6996a84cecb39a600b3eee80https://doi.org/10.1158/1557-3265.sabcs25-ps5-04-27
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world progression-free survival and overall survival in patients with HR<sup>+</sup>/HER2<sup>-</sup> advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study.2026
  2. 2Abstract PS1-12-06: Ribo-age: age-stratified descriptive analysis of adverse drug reactions in patients with advanced breast cancer treated with ribociclib plus nonsteroidal aromatase inhibitors: preliminary results2026
  3. 3Abstract PO3-16-10: Real-world outcomes with first-line ribociclib + endocrine therapy in patients with metastatic HR+, HER2– breast cancer: Fourth interim analysis of REACH AUT trial2024 · 2 citations
  4. 4Abstract PD5-10: Pooled analysis of patients (pts) treated with 1st-line (1L) ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA (ML) studies: long-term progression-free survival (PFS)2026 · 2 citations
  5. 5Abstract PS02-01: Efficacy, safety, and quality of life with ribociclib + endocrine therapy in elderly patients with HR+/HER2– advanced breast cancer across the MONALEESA-2, -3, and -7 trials2024 · 1 citations